

## University of Leeds (UnivLeeds)

The Section of Musculoskeletal Disease (MSKD) is acknowledged as a world leader in inflammatory disease. MSKD is in the Leeds Teaching Hospitals Trust, the largest NHS Trust in the UK (turnover £ 760m) and the University of Leeds, the II largest University in the UK (turnover £ 400m) and one of the largest biomedical research universities. In addition to a recent collaborative FP7 grant (€18M), the National Institute for Health Research (NIHR) has recently awarded the Leeds Teaching Hospitals Trust (LTHT) and the University of Leeds a prestigious establishment grant (£ 6m) to become the NIHR Leeds Musculoskeletal Biomedical Research Unit (LMBRU). Research Units have been established by the NIHR: Leeds was identified as an international leader in musculoskeletal disease research. This funding will formalise collaborations between the Institute of Medical and Bioengineering and MSKD to create an integrated unit which will become the UK's leading musculoskeletal research facility.

## Key Staff

Professor **Paul Emery**. Arthritis Research Campaign (arc) Professor of Rheumatology, he is recognised as a world authority in the pathogenesis and novel management of early inflammatory arthritis. In the past six years, he generated more than £ 12 million in competitive grant income and has over 550 peer reviewed publications. He is President of the European League Against Rheumatism (EULAR) from 2009-2011 and UK Member of the European Science Foundation Rheumatology. He's scholarly activities have included significant contributions to the biological basis of disease through exploring the role of cyclosporin and demonstration that locally delivered anti T-cell therapy was effective and, more recently, the efficacy of B-cell. Emery developed MSK ultrasound as a standard outcome measure in IA. He explored the pathogenesis of inflammatory arthritis, including early arthritis for demonstration of very early lesions, and the fact that damage occurs early, mode of action studies for novel agents and demonstration that remission with conventional disease modifying drugs fails to prevent damage because of insufficient suppression of inflammation.

Professor **Phillip Conaghan**. Prof. of Musculoskeletal Medicine, he is an international leader in imaging and imaging outcomes. He is Chair of the EULAR Standing Committee on Imaging, Co-Chair of the Imaging in Inflammatory Arthritis Task Force and the Ultrasound Task Force for the Outcome Measurement in Rheumatology (OMERACT) International Group; Research Lead for the International Society for Extremity MRI in Rheumatology (ISEMIR). Conaghan has published over 100 journal articles and is a leading Osteoarthritis researcher, is Chair of NICE Guideline Development Group for Osteoarthritis and is the Chair of the arc Osteoarthritis and Related Disorders Clinical Scientific Group.

Dr **Anne-Maree Keenan** is an AHP Research Fellow within MSKD and has a strong grant and publication record, including clinical trials and epidemiological research methods.

## Contacts

University of Leeds  
Section of Musculoskeletal Disease, LIMM  
Woodhouse Lane  
LS2 9JT Leeds  
United Kingdom  
Tel: +44 113 392 4884  
Fax: +44 113 392 4991  
Web: <http://www.leeds.ac.uk/>